Browse Full Report with TOC at: http://www.researchmoz.us/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsedrefractory-setting-report.html It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).

1. Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting
GBI Research, the leading business intelligence provider, has released its latest research: ‘Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets
to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting ’, which provides in-depth insights into the indication. It gives
an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It
also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and
analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to
grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase
inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers.
The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor
everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An
increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation
of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance,
especially in India, stand to curtail the APAC NHL market.
Scope A brief introduction to NHL, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms In-depth analysis of currently
marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms
of safety and efficacy A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to
enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and
molecular target Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key
patents on current drugs and the changes in disease epidemiology across the key developed markets Discussion of the drivers of and barriers to market growth
In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006 Reasons to Buy Understand the NHL pipeline
and the factors that indicate that it is becoming more innovative Examine detailed profiles of promising pipeline products and gain an insight into how they are
likely to compete in the market and who their main competitors will be Follow the trends in NHL clinical trial size and duration in relation to industry averages
and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates Observe
the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this
growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the NHL market Accelerate and strengthen your
market position by identifying key companies for strategic partnerships
table Of Content
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.4 Diagnosis
2.4.1 Biopsy
2.4.2 Laboratory Molecular Tests
2.4.3 Imaging Tests
2.5 Classification
2.5.1 B-cell Lymphomas
2.5.2 T-cell Lymphomas
2.6 Epidemiology
2.7 Prognosis And Disease Staging
2.7.1 Staging
2.8 Treatment Options
2.8.1 Surgery And Radiation Therapy
2.8.2 Stem Cell Transplantation
2.8.3 Pharmacological
2.8.4 Treatment Algorithms And Prescribing Habits
2.9 Gbi Research Report Guidance
3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Immunotherapies
3.1.2 Targeted Therapies
3.1.3 Chemo-regimens
3.2 Comparative Efficacy And Safety (marketed Products)
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

2. 4 Pipeline Products
4.1 Overall Pipeline
4.2 Pipeline Analysis By Molecule Type
4.3 Pipeline Analysis By Mechanism Of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Patient Enrollment And Clinical Trial Size
4.4.3 Duration
4.5 Promising Drug Candidates In The Pipeline
4.5.1 Idelalisib (gs-1101) – Gilead Sciences
4.5.2 Imbruvica (ibrutinib) – Pharmacyclics/janssen Biotech
4.5.3 Gazyva (obinutuzumab) – Roche
4.5.4 Revlimid (lenalidomide) – Celgene
4.5.5 Afinitor (everolimus) – Novartis
4.6 Heat Map Of Safety And Efficacy And Product Competitiveness Framework For Non-hodgkin Lymphoma Pipeline
5 Market Forecast To 2019
5.1 Geographical Markets
5.1.1 Apac Market
5.1.2 India
5.1.3 Australia
5.1.4 China
5.1.5 Japan
5.2 Drivers And Barriers For The Disease Market
5.2.1 Drivers
5.2.2 Barriers
6 Deals And Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 Roche Signs An Agreement With Glycart And Genentech
6.1.2 Cell Therapeutics Enters Agreement With Bayer
6.1.3 Chugai Enters Co-development Agreement With Nippon Shinyaku For Ga101
6.1.4 Glaxosmithkline Enters Co-development Agreement With Genmab
6.1.5 Biogen Idec Enters Co-development Agreement With Genentech
6.1.6 Seattle Genetics Enters Co-development Agreement With Millennium
6.2 Major Licensing Deals
6.2.1 Spectrum Enters Licensing Agreement With Bayer For Zevalin
6.2.2 Janssen Biotech Enters Licensing Agreement With Pharmacyclics For Pci-32765
6.2.3 Lundbeck Enters Licensing Agreement With Cephalon
6.2.4 Tg Therapeutics Enters Licensing Agreement With Ildong For Ublituximab
6.2.5 Provenance Enters Licensing Agreement With Merck Serono
6.2.6 Cephalon Enters Licensing Agreement With Symbio
6.2.7 Genentech Enters Licensing Agreement With Seattle Genetics
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 Pipeline Tables
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Investigational New Drug-filed
7.4.4 Phase I
7.4.5 Phase Ii
7.4.6 Phase Iii
7.5 Market Forecasts To 2019
7.5.1 Asia-pacific
7.5.2 India
7.5.3 Australia
7.5.4 China
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

3. 7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting